(NP (NP (NP (ADJP (FW In) (FW vivo)) (NN footprint) (NN analysis)) (PP (IN of) (NP (DT the) (NN HLA-DRA) (NN gene) (NN promoter))) (: :)) (NP-COOD (NP (NP (JJ cell-specific) (NN interaction)) (PP (IN at) (NP (DT the) (NN octamer) (NN site)))) (CC and) (NP (NP (NN up-regulation)) (PP (IN of) (NP (NN X) (NN box) (NN binding))) (PP (IN by) (NP (NN interferon) (NN gamma)))) (. .)))
(S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (DT the) (JJ major) (NN histocompatibility) (NN complex) (NN class) (CD II) (NN gene) (NN promoter) (NN DRA)))) (VP (VBZ has) (ADVP-TMP (RB previously)) (VP (VBN identified) (NP (NP (QP (IN at) (JJS least) (CD five)) (JJ cis-acting) (NNS regions)) (VP (VBN required) (NP (-NONE- *)) (PP (IN for) (NP (JJ maximal) (NN expression))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NN DRA) (NN promoter)) (PP (IN for) (NP (NP (JJ protein-DNA) (NNS interactions)) (PP (IN in) (NP (DT the) (JJ intact) (NN cell))))) (, ,) (SBAR (WHNP-24 (WDT which)) (S (NP-SBJ (-NONE- *T*-24)) (VP (MD may) (VP (VB mediate) (NP (JJ transcriptional) (NN activation))))))))) (. .))
(S (S-ADV (NP-SBJ (-NONE- *-25)) (VP (VBG Using) (NP (ADJP (FW in) (FW vivo)) (JJ genomic) (NN footprinting)))) (NP-SBJ-25 (PRP we)) (VP (VBD identified) (NP (NP (NNS interactions)) (PP (IN in) (NP (NN B-cell) (NNS lines)))) (PP (IN at) (NP-COOD (NP (DT the) (NN octamer) (NN site)) (CC and) (NP (DT the) (NP-COOD (NP (NN Y)) (, ,) (NP (NN X1)) (, ,) (CC and) (NP (NN X2))) (NNS boxes))))) (. .))
(S (NP-SBJ (NN Class) (CD II) (NN antigen) (VBG expressing) (NN T-cell) (NNS lines)) (VP (VBD maintained) (NP (NP (NNS contacts)) (ADJP (JJ identical) (PP (TO to) (NP (NN B-cell) (NNS lines))))) (, ,) (SBAR (IN while) (S (NP-SBJ (ADJP (NN class) (JJ II-negative)) (NN T-cell) (NNS lines)) (VP (VBD exhibited) (NP (DT no) (NNS interactions)))))) (. .))
(S (PP (IN In) (NP (JJ lymphoid) (NN cell) (NNS lines))) (, ,) (NP-SBJ-26 (DT the) (NN octamer) (NN site)) (VP (VBZ is) (VP-COOD (VP (VBN occupied) (NP (-NONE- *-26))) (CC and) (VP (VBN required) (NP (-NONE- *-26)) (PP (IN for) (NP (JJ maximal) (NN expression)))))) (. .))
(S (NP-SBJ (DT This)) (VP (VBZ is) (PP-PRD (ADVP (RBS most) (RB likely)) (JJ due) (TO to) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (JJ lymphoid-specific) (NN OTF-2) (NN factor)))))) (. .))
(S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (DT the) (ADJP (NN class) (JJ II-positive)) (JJ nonlymphoid) (NN glioblastoma) (NN cell) (NN line)) (VP (VBZ does) (RB not) (VP-COOD (VP (VB exhibit) (NP (NNS interactions)) (PP (IN at) (NP-102 (DT the) (NN octamer) (NN site))) (PP (IN despite) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (JJ ubiquitous) (NN OTF-1) (NN factor)))))) (CC and) (VP (NP=102 (DT an) (JJ open) (VBG binding) (NN site))))) (. .))
(S (ADVP (RB Thus)) (, ,) (NP-SBJ (DT the) (NN DRA) (NN promoter)) (VP (VBZ discriminates) (PP (IN against) (NP (NP (NN OTF-1) (NN activation)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN DNA) (NN binding))))))) (PP (IN in) (NP (DT the) (NN glioblastoma) (NN line)))) (. .))
(S (NP-SBJ (NN Interferon) (NN gamma)) (VP-COOD (VP (VBZ induces) (NP (NN class) (CD II) (NN expression)) (PP (IN in) (NP (DT this) (NN glioblastoma) (NN cell) (NN line)))) (CC and) (, ,) (VP (PP (IN in) (NP (NN parallel))) (, ,) (VBZ up-regulates) (NP (NP-COOD (NP (NN X1)) (CC and) (NP (NN X2))) (NN box) (JJ protein-DNA) (NNS interactions)) (, ,) (SBAR (IN while) (S (NP-SBJ (DT all) (JJ other) (NNS interactions)) (VP (VBP remain) (ADJP-PRD (JJ unchanged))))))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-28 (NN interferon) (NN gamma)) (VP (VBZ functions) (PP (IN on) (NP (DT a) (VBN poised) (NN promoter))) (PP (IN by) (S (NP-SBJ (-NONE- *-28)) (VP (VBG altering) (NP (NP (JJ weak) (, ,) (JJ nonproductive) (NNS interactions)) (PP (IN at) (NP (DT the) (NN X) (NNS boxes)))) (PP (TO to) (NP (JJ strong) (NNS interactions)))))))))) (. .))
(S (NP-SBJ (DT These) (NNS findings)) (VP (VBP provide) (NP (JJ direct) (ADJP (FW in) (FW vivo)) (NN evidence) (S (NP-SBJ (-NONE- *)) (VP (TO to) (ADVP (RB strongly)) (VP (VB suggest) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN modulation)) (PP (IN of) (NP (NP-COOD (NP (NN X1)) (CC and) (NP (NN X2))) (NNS interactions)))) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ important) (NN constituent)) (PP (IN of) (NP (DT the) (NN interferon) (NN gamma) (NN induction) (NN pathway)))))))))))) (. .))
